| Basics |
Chimerix, Inc.
Chimerix Inc is a biopharmaceutical company which focuses on the discovery, development, and commercialization of novel, oral antivirals in areas of unmet medical needs.
|
| IPO Date: |
April 11, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$802.02M |
| Activated in VL: |
False |
| Average Daily Range |
| Avg Daily Range: |
$0.27 | 2.90%
|
| Avg Daily Range (30 D): |
$0.01 | 0.13%
|
| Avg Daily Range (90 D): |
$0.09 | 2.22%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.82M |
| Avg Daily Volume (30 D): |
1.53M |
| Avg Daily Volume (90 D): |
3.11M |
| Trade Size |
| Avg Trade Size (Sh.): |
204 |
| Avg Trade Size (Sh.) (30 D): |
303 |
| Avg Trade Size (Sh.) (90 D): |
364 |
| Institutional Trades |
| Total Inst.Trades: |
1,039 |
| Avg Inst. Trade: |
$1.51M |
| Avg Inst. Trade (30 D): |
$1.21M |
| Avg Inst. Trade (90 D): |
$2.2M |
| Avg Inst. Trade Volume: |
.16M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.44M |
| Avg Closing Trade (30 D): |
$1.14M |
| Avg Closing Trade (90 D): |
$1.12M |
| Avg Closing Volume: |
148.16K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-.99
|
$-.26
|
$-.99
|
|
Diluted EPS
|
$-.99
|
$-.26
|
$-.99
|
|
Revenue
|
$ .21M
|
$ .06M
|
$ .21M
|
|
Gross Profit
|
$ .21M
|
$
|
$ .21M
|
|
Net Income / Loss
|
$ -88.39M
|
$ -22.95M
|
$ -88.39M
|
|
Operating Income / Loss
|
$ -96.57M
|
$ -24.55M
|
$ -96.57M
|
|
Cost of Revenue
|
$ M
|
$
|
$ M
|
|
Net Cash Flow
|
$ 3.39M
|
$ 7.4M
|
$ 3.39M
|
|
PE Ratio
|
|
|
|
|
